Remus Pharmaceuticals Limited — Important, 09-11-2024: Financial Result Updates

Remus Pharmaceuticals Limited reported robust financial results for the half-year ended September 30, 2024, with total revenue soaring to ₹27,555.54 Lakhs, marking a 797.60% increase year-over-year. EBITDA increased to ₹233.78 Lakhs, showing 113.99% growth, while Profit After Taxes rose to ₹1,401.12 Lakhs, up 148.09%. The Board approved a 10% interim dividend of ₹1.00 per share, with a record date set for November 20, 2024.